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 ABSTRACT 
 
Background and Purpose: Ménière’s disease is not uncommon, with an incidence in 
Caucasians of about one in 2000.  The incidence peaks in the fifth decade.  Cases are usually 
isolated or sporadic, but in perhaps five per cent other family members are affected.  We 
report here the clinical and genetic characteristics of a comprehensive set of familial MD 
cases from the U.K. 
Methods: Forty-six affected families have been studied. All cases were diagnosed using 
AAO-HNS CHE 1995, or more stringent, criteria.   
Outcome/Results: Autosomal dominant inheritance with reduced penetrance was the most 
likely mode of inheritance overall. Apparent genetic anticipation is observed, but may also be 
a result of ascertainment bias given the collection strategy. There was also a slight tendency 
for cases to result from maternal transmission within the families in this set. The family 
pedigrees are presented and a website has been set up to allow professionals to view the 
family set in greater detail. (148 words) 
 
Key Words: Ménière’s disease. Familial. Epidemiology. Genetics. Dominant. Anticipation
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INTRODUCTION 
 
Ménière’s disease comprises a defined clinical entity, in which the sufferer experiences 
sudden and recurring episodes of vertigo often with nausea and vomiting, together with 
hearing loss and tinnitus, usually occurring in just one ear at onset.  A feeling of fullness or 
pressure in the affected ear is common. Typically around the time of a Ménière’s vertigo 
attack the fullness and tinnitus will exacerbate and the hearing loss will become worse, then 
recovering fully or partially after the episode. The disease runs in quiescent and then in more 
active periods in which there are more frequent or more severe vertigo attacks, often 
remaining troublesome for a few months at a time. Between attacks balance frequently returns 
to normal, but in active periods some continuous disequilibrium and vague dizziness may 
persist.  Initially the hearing loss tends to be fluctuating and spontaneously reversible. Over 
years however it becomes more permanent and progressive. Eventually the condition “burns 
out”: the vertigo attacks more or less cease completely, but by this time the hearing loss can 
be severe.  Over time there is an increasing likelihood of involvement of the second ear, 
leading to the disease becoming bilateral. The American Academy of Otolaryngology-Head 
and Neck Surgery Committee on Hearing and Equilibrium (AAO-HNS CHE) 1995 guidelines 
for the diagnosis of MD are widely accepted 1 and diagnosis requires the combined presence 
of 3 different clinical features: (i) at least two attacks of vertigo lasting 20 minutes or longer, 
(ii) the presence of either aural fullness or tinnitus (or both) and (iii) a sensorineural hearing 
loss on the affected side of at least 25dB worse than that on the non-affected side, (taken as 
the average threshold for 0.05, 1.0, 2.0 and 3.0 kHz). 
 
Incidence. Ménière’s disease (MD) usually arises de novo in midlife (i.e. after the usual age 
of reproduction), less commonly in younger adults or in the elderly, and rarely in children. 
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The data in grey bars in Figure 1 show the age of onset distribution of 406 sequential patients 
presenting to the authors with sporadic MD. These new data are an extension of the 
previously published series 2. Figure 1 also shows, for comparison, the younger age of onset 
distribution found in familial MD cases (black bars), based on the 46 families being reported 
in this paper. 
 
Globally the great majority of Ménière’s cases are sporadic, there being no other close family 
members similarly affected.  Reported cumulative lifetime incidence for MD varies greatly, 
ranging from as low as 0.8 per 1,000 in Italy 3 to as high as 1.57 per 1,000 in the UK 4.  
Harrison and Naftalin 5 proposed a UK figure of 1 per 1000, which seems a fair estimate.  In 
1983 Watanabe 6 reviewed the published reports. Frieberg and Stahle did so more recently 7.  
In Finland, an extrapolated prevalence estimate of 0.43 per 1,000 was reported 8. The Swedish 
figure 9 of 0.46 per 1,000 (circa 1 in 2000), coming from a well-documented homogeneous 
population, seems the most acceptable. 
 
Ethnic Distribution.  Ménière’s Disease is predominantly a disease of Caucasians or 
Eurasians.  In 1963, a report from the USA described it as a disease of whites, seldom seen in 
those of African origin 10.   In 1964 Fick 11 reported its rarity in the Bantu.  A similar picture 
came from the West Indies in 1967 12.  Gibson commented on its rarity in those of Afro-
Caribbean origin 13. Also in 1979, Wiet noted the near absence of MD in American Indians 14.  
In Japan the incidence is lower than in Europe, at about 0.035 - 0.160 per 1,000 depending 
upon which survey is accepted 6.  All these findings support the conclusion that incidence of 
MD varies between populations of different continents . 
 
 
 5 
Familial Ménière’s disease is now a well-recognised entity, but was not in 1941 when 
Brown 15 described two brothers with MD whose symptoms had started at ages 49 and 50, 
respectively.   She followed this with a second report in 1949 of two families 16.  The first 
consisted of three definite MD patients from a sibship of five, the normal parents being first 
cousins. The mother had two brothers both of whom had an affected son. The second family 
consisted of identical twin boys, both deaf, but only one with dizzy spells for about two years; 
the hearing losses were conductive on clinical and audiometric testing; the diagnosis was 
probably otosclerosis.  
 
After a gap of nearly twenty years, in 1965, Bernstein 17 published on familial deafness and 
vertigo.  In 1967 Hinchliffe’s 18 clinical record on psychosomatic aspects of MD contains 
mention of familial cases but it is difficult to assess their frequency; we can surmise that there 
were perhaps two affected sib pairs from 42 cases, giving a frequency of approximately 5%.  
 
There was another significant hiatus until 1981, when Morrison 19 reported that five of 190 
patients with MD had a positive family history, a frequency of 2.6 per cent.  About the same 
time an epidemiological study from Japan 20 found that 5.8 per cent of MD patients had an 
affected close relative.  In 1992 there was also a report of two Italian families by Martini 21. 
Two further publications merit comment.  In 1984, from Sweden, Birgerson et al 22 reported 
the frequency of familial MD to be as high as 12 per cent (11 familial from 91 MD patients); 
the latter figure is based largely on a questionnaire, which can be misleading: this paper was 
largely reproduced in 1987 23.  A recent paper from Finland gives a comparable figure of 
approx. 15 per cent 24.  In our second paper, also in 1987 25, we reported 35 first degree 
relatives from a series of 671 confirmed MD patients (5.4 per cent) rising to an overall 
frequency of familial cases of 7.7 per cent if second and third degree relatives were included:  
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these figures however were extracted from the family history in clinical records without 
actual diagnostic confirmation in many of the relatives. The 5.4% in first-degree relatives is 
probably reasonably accurate. Two further recent reports 26, 27 describe medium-to-large 
multiply-affected families.  
 
 If familial MD was encountered in clinical practice with a frequency as high as 7.7 % or 12 
%, this finding would be very apparent. The paucity of such reports over the years and the 
difficulty in collecting a sizeable series argues against such figures.  One is left with the 
impression that a figure for the frequency of familial MD of 5 per cent at most, possibly less, 
would be more realistic. In summary, there seems to be a case for believing that 
predisposition to MD, at least in a proportion of cases, has a significant genetic component.  
Two of the commonly accepted criteria are observed - differences in disease incidence 
between populations and familial clustering.  The third recognised criterion, evidence or 
report of greater concordance in monozygotic than dizygotic twins, has not been reported, 
presumably because of the relative rarity of affected twins. 
  
MATERIALS AND METHODS 
 
THE FAMILIAL SERIES.   
 
Ascertainment - Our search for UK Caucasian families with more than one living member 
considered to have MD started in 1992. The majority were ascertained in the first few years 28, 
29. Most came from private practice, a few from the UK National Health Service (NHS), some 
from a circular letter to UK ENT surgeons, and a small number from the Ménière’s Society, a 
patient support group.  In 1993, after the 6pm Carlton TV news, the senior author (AWM) 
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was given a few minutes to appeal for such families; hundreds of letters were forwarded, but 
only six possible families were ascertained. 
 
A circular letter was given, or sent, to all propositi requesting a copy of their family tree based 
on a provided example.  Likely MD families were contacted and requested to attend with 
appropriate unaffected family members, all expenses being offered.  The response and 
cooperation was one hundred per cent.   The family pedigrees and clinical data were collected 
and assimilated using Cyrillic 2 software (Cherwell Scientific Publishing Ltd.). Ethical 
approval for this ongoing work and our subsequent genome search for genes predisposing to 
MD was obtained from Cambridge Local Research Ethics Committee, REC ref 02/375.  
 
Exclusion criteria - After examination, several families were excluded, only one member 
having classical MD, the other(s) having any of a variety of other vestibular problems.  One, 
for example, had MS, one a moderately large acoustic neuroma, one otosclerosis plus BPPV 
and another, the Chiari malformation. There were three children with a congenital anomaly of 
one ear who, in childhood, developed the classical features of MD, one having, on CT 
scanning, an osseous dilatation of the superior semicircular canal. 
 
The family set - By 1994, from twelve possible families, only eight were suitable for 
inclusion in a paper also concerned with environmental factors 28.  By 1995 29 after further 
exclusions, forty-one families with eighty-nine MD-affected cases were included in the series 
and by 2002 2 the series consisted of 46 families with 118 affected individuals. Since then, 
some of these have been excluded after revision of their diagnosis. Many of the families have 
been followed up at regular intervals by one or other of the authors over the past fourteen 
years.  A few new families have been added. 
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The total series now comprises 61 families who were investigated with a possible history of 
familial Ménière’s disease. 60 contain >1 sufferer of MD or one MD case and one or more 
with partial vestibular syndromes but not certain MD. Of these, 46 families have currently 
been confirmed as having two or more family members with classical Ménière’s disease.  
 
Sampling - Affected and unaffected family members gave venous blood samples from which 
genomic DNA was extracted at St Mary’s Hospital Medical School, London or at the 
Regional Genetics Laboratory at Addenbrooke’s Hospital in Cambridge. Repeat samples were 
also stored at Addenbrooke’s. Being a disease of late onset, unaffected youngsters below the 
age of 16 were not subjected to venepuncture. 
 
Clinical characterisation.  Diagnostic schema - Personal interview and full clinical 
examination by the authors confirmed the diagnosis in almost all cases. In a few, other British 
Otologists established the diagnosis. A detailed history was taken for each family member. 
Diagnosis in suspected cases was backed up by laboratory investigation 30. The American 
Academy Of Otolaryngology-Head and Neck Surgery (AAO-HNS) Committee on Hearing 
and Disequilibrium (CHE) has issued guidelines three times on the diagnosis and treatment 
assessment, in 1972, 1985 and 1995 31, 32,1. The 1995 AAO-HNS CHE guidelines are widely 
accepted. As mentioned above, a diagnosis of full/definite MD requires satisfaction of at least 
three clinical and audiometric criteria, either tinnitus or aural fullness, at least two attacks of 
vertigo lasting 20 minutes or longer, and sensorineural hearing loss on the affected side of 25 
dB or worse. There is a severity staging system based only on the average hearing thresholds, 
Stage 1 being<=25dB: Stage 2 being 26-40dB: Stage 3 measuring 41-70dB: and Stage 4 
>70dB. There is also a functional scale based on patient selection of the best fit of six 
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questions describing increasing incapacity in relation to vertigo-related symptoms.  
 
Our collection of the familial MD series started in 1992, three years before the AAO-HNS 
CHE guidelines appeared. We initially employed our own severity classification (on a scale 
of 1-3), which depended, to some extent, upon when the patient was first examined in relation 
to the natural history.  In the very early stages there can be a diversity of vertiginous 
symptoms such as transient dizziness with fluctuant hearing loss, later classical episodes 
lasting up to 24 hours, and with the passage of time, amelioration with shorter and less violent 
attacks. In the later stages, when there is more marked hearing loss, attacks can be replaced by 
vague dizziness and instability. 
 
In our classification bilateral disease and drop attacks were designated class 3, likewise those 
whose symptoms were so severe as to be incapacitating, equating to the AAO-HNS CHE 
scales 4, 5 or 6. For hearing loss severity, our classification, though not based on deafness 
levels, turned out to be similar to AAO-HNS CHE; stage 1 patients mostly had moderate 
losses of up to 35dB; our stage 2, losses of 35dB-50dB; and stage 3, losses over 50dB, 
sometimes subtotal.  During follow-up in many families over the fourteen years some scaling 
changes were made, usually for the worse, based mainly on the deafness severity or the need 
for destructive surgery.  A few deaths have occurred among both affected and unaffected. 
 
Stahle et al 33 have reviewed the natural history confirming that, with the passage of time, 
second ear involvement increases, approaching 50 per cent after 20 years.  They found that 
the main cochlear and vestibular symptoms and damage were in the first five to ten years and 
that thereafter hearing thresholds stabilised at 50dB-60dB.  Morrison 34 in an assessment of 
330 patients with sporadic MD was in general agreement save that after fifteen years 
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continued hearing deterioration was noted.  This also applies to familial MD cases, some 
finishing with sub-total hearing loss. An examination of the cochlear implant literature will 
confirm this. 
 
Reclassifications - Partial Syndromes.   
 
Prior papers on our families 2, 28, 29 have included a few individuals labelled vestibular or 
cochlear MD.  The 1972 AAO-NHS CHE guidelines 31 included both of these sub varieties.  It 
was assumed, as with any such study, that phenocopies had been excluded.  The 1995 
criteria 1 exclude such variants, instead defining Probable and Possible MD accepting that 
over time the full symptom complex could develop. 
 
Probable MD is defined as one definite episode of vertigo and audiologically documented 
hearing loss on at least one occasion and tinnitus or aural fullness in the affected ear.   
 
Possible MD has two definitions:- 
1. Episodic vertigo of the Ménière type without documented hearing loss. 
2. Sensorineural hearing loss, fluctuating or fixed, with disequilibrium but without 
definite episodes. 
We have re-examined all the previously designated cases with partial syndromes and altered 
them to the most recent AAO-HNS CHE guidelines.  The reclassified status of these 
individuals is not always an accurate reflection of their clinical phenotype.  Take, for 
example, the individual IV:4 in Family MX (see Figure 3).  This lady has episodic classical 
attacks lasting two to four hours, on and off for years.  Prior to each attack, she experiences 
tinnitus and an uncomfortable blocked sensation (? hearing loss), always in her right ear, but 
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no hearing loss has ever been documented.  This now has the lesser description of Possible 
MD.  When considering partial syndromes, it is well to remember that though half of MD 
patients develop the full symptom complex within six months, one third experience deafness 
and tinnitus only and one fifth episodic vertigo alone for periods in excess of six months, 
sometimes even for years 34.  During the first five years, in a substantial majority, hearing 
thresholds can revert to normal limits 34. Thus in a near certain MD case, objective hearing 
loss may be missed.  As will be seen, our efforts have concentrated on families most likely to 
be of use in genetic analysis; in these the length of follow-up excludes misdiagnoses. 
 
Episodes of Positional Vertigo frequently occur in MD. Sometimes a true attack starts in bed 
when turning on the affected side.  At some stage in the natural history, usually when well 
developed, many patients experience transient positional episodes indistinguishable from 
classical benign paroxysmal positional vertigo (BPPV). These are recorded in the pedigree, as 
are the finding of unaffected relations also with BPPV.  There are several causes of positional 
vertigo that have been analysed by Morrison and Morrison 35.  The two commonest are, 
firstly, idiopathic (44 per cent) and, secondly, following one or more attacks of vestibular 
failure (22 per cent) usually presumed to be viral. These both have features in common 
including a 3:2 female/male ratio, an onset age showing a normal distribution around the fifth 
decade, and active and quiescent spells, akin to MD. Hearing is unaffected. The Hallpike 
manoeuvre confirms the peripheral nature, a short latent period, rotary nystagmus to the 
undermost ear, adaptation and fatigue, all implicating the posterior canal ampulla, presumably 
due to cupulothiasis or canalithiasis. Many of these family members have repeated episodes 
of BPPV over years whether idiopathic in origin or following acute vestibular failure. The 
clinical diagnosis of isolated benign paroxysmal positional vertigo (BPPV) however is very 
distinct from that of MD with associated peripheral type positional vertigo, since in BPPV 
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there is no fullness, tinnitus or hearing loss. The pathophysiology of BPPV is considered to 
result from otolith crystals and debris becoming freed and then misplaced within the 
labyrinth, and it is likely that any cause of vestibular end organ damage can lead to this 
phenomenon. BPPV can therefore occur with classical symptomatology and be secondary to 
Ménière’s Disease. 
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RESULTS - The Pedigrees 
 
From the originally investigated entire set of 61 families, 137 patients with Ménière’s Disease 
and 41 other patients with partial vestibular syndromes were identified. 
 
Of these 61 families, 15 families were eventually excluded from further consideration, 
leaving 46 families confirmed as having two or more family members with classical 
Ménière’s disease (definite MD under the AAO-NHS CHE 1995 criteria), yielding 120 
affected individuals in total. Twenty-two other patients were classified with a partial 
syndrome, either probable or possible Ménière’s Disease or occasionally with isolated 
idiopathic benign paroxysmal positional vertigo (BPPV). In several of the 46 families there 
were individuals with non-MD-related causes of hearing loss (e.g. post-infection or 
congenital). 
 
Of the excluded 15 families, at the end point of this study, 14 have been confirmed to have 
only one member with classical Ménière’s disease, with other dizzy patients in those families 
being categorised with partial syndromes. One further family has one member with Ménière’s 
disease and one member with a congenital ear anomaly only. 
 
From the series of 46 confirmed multiply-affected families, the 18 pedigrees that were 
considered most appropriate for our genetic analysis (implemented in a subsequent Genome 
Scan, manuscript in preparation.) are published here in full electronically, in the Journal of 
Laryngology & Otology (electronic reference to be inserted) and a recently added 19th family 
(family A-A) is included.  A further 9 families were included as part of a larger screening 
panel of affectands and some of these were used in screening for candidate genes (manuscript 
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in preparation). This entire series of 46 pedigrees, in ongoing draft research format can be 
seen in full at www.GavinMorrison.com.  
 
Inheritance patterns and parameters –  
 
Of the 46 families, 27 have 2 affectands, 12 have 3 affectands, 6 have 4 affectands and one 
family has had 5 members with Ménière’s Disease. Of those families (n = 14) with affected 
sibling pairs, 10 also have one affected parent and 4 have parents without disease. 
 
Sex ratios  In the entire set of 61 families with cases of definite MD there are a total of 75 
affected females and 62 males, giving a female : male ratio of 1.21. This is a weaker female 
predominance than previously noted 29.  Interestingly however, if the sex ratio of the patients 
with partial syndromes is included (31 females and 5 males) the female preponderance 
becomes much stronger (F:M = 106:67, approximately 1.6 : 1).  Amongst the 46 families with 
multiple MD affected members, 63 definite MD cases were female and 57 were male, again 
only a marginal predominance of females. 
 
Age of onset & Anticipation – The distribution of age of onset for the familial cases in our 
series is shown in Fig. 1. The age of onset in familial cases differs from sporadic MD, the 
peak onset being in the fourth rather than the fifth decade. Genetic anticipation describes the 
phenomenon of progressively younger onset and more severe affectation of a genetic disease 
in succeeding generations. Thus far, every confirmed example of anticipation has been shown 
to involve a causal pathway characterised by mutation of specific tracts of DNA sequence 
consisting of 3-base tandem repeats (trinucleotide repeats), where increased severity and 
decreased age of onset are associated with increases (expansions) in the number of repeats 
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present in each successive generation, (hence, trinucleotide repeat expansions). Our 
pedigrees, with few exceptions, demonstrate apparent anticipation, certainly regarding age of 
onset, and to a lesser extent regarding disease severity; this was also reported previously 28, 29.  
Thus the age at onset in the child is earlier than that in the parent in all but one of the parent-
offspring pairs in our family set. Figure 2 demonstrates this apparent anticipation graphically 
with all points appearing on or below the line.  In the 35 patients with an age of onset under 
30 years, ten have bilateral disease suggesting that severity is increased in families with early-
onset cases, perhaps reflecting a stronger genetic influence on predisposition. The incidence 
of bilateral disease in sporadic MD in those under 30 years old, in comparison has never been 
reported but the authors estimate it to be no greater than 10% - 15 %.  Some caution should be 
exercised over this conclusion of anticipation however, since from our series the proband (or 
propositus) was the immediate offspring or close relative of another affected individual in 22 
families, while the proband originated from the highest generation in only 8 families.  (The 
proband was in the same generation as other affected members in a further 12 families). This 
preponderance of younger probands may therefore represent some ascertainment bias in the 
analysis of anticipation. 
 
Examining the 19 family pedigree published electronically here in full (electronic JLO journal 
reference), 55 patients had MD, of whom 12 were bilaterally involved. Of these 55, 23 were 
classified as stage 3 (severe) disease, 23 were classified as stage 2 and only 7 were found to 
be stage 1 (mild) disease. Of these 19 families, 15 showed a progression in the staged severity 
of disease through a descending generation, while only 3 showed no progression and only one 
exhibited a less severe grade in descendants. These individual data are available on the 
pedigree charts for the entire series at www.GavinMorrison.com. 
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Mode of inheritance  
 
Of the 46 families, 32 exhibit direct transmission from parent to offspring. In 20 cases there 
was a parent transmission to one offspring, in 11 cases there was a parent transmission to two 
offspring and in one case a direct transmission to 3 offspring was noted. Three families also 
show a linear transmission directly through two generations from grandparent to parent to 
child. Male to male transmission is observed and there is no evidence for genomic imprinting, 
which would be characterised by transmission of the disease to offspring of either sex from 
parents of one sex only. The predominant pattern visible in the family pedigrees is most 
consistent with autosomal dominant inheritance.  Under this hypothesis, we estimate 
penetrance in all 46 families to be about 60%, some pedigrees appearing to have segregation 
ratios consistent with full penetrance. Family GW, (figure 3) is a typical example of one of 
the pedigrees showing apparent autosomal dominant inheritance. Some of the families are 
also consistent with autosomal recessive inheritance, particularly MX (figure 3) in view of the 
consanguinity in this family. Two of four offspring of the unaffected cousin marriage in MX 
are affected, however (we consider individual IV:4 likely to be affected although we have not 
treated her as definite MD in our analyses; see foregoing discussion in Methods section on 
diagnosis and partial syndromes), and the third affected is in the parental generation, making 
recessive transmission less likely unless a common allele exists in the population (three 
mutation-carrying founders are required if the true mode of inheritance is recessive versus one 
if it is dominant). Overall, there is no compelling evidence in favour of recessive inheritance 
in this set of families.  
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Sex-ratio transmission bias 
 
Transmission ratios are biased (P < 0.001 Fisher’s Exact Test for overall comparison), as 
illustrated in Table 1. Females tended to transmit to female offspring and males to male 
offspring (P<0.001 and P<0.05, respectively; Chi-squared tests with continuity correction, 1 
d.f.). There is also an overall bias favouring transmission from mothers over transmission 
from fathers (P<0.04; Chi-squared with continuity correction = 4.4). The interpretation of 
these data, however, has to be made bearing in mind that from our series, for all female 
affectands who showed direct MD transmission to their offspring, there were a total of 40 
female offspring and only 27 male offspring (affected and unaffected children).  Affected 
transmitting fathers also showed a female-biased offspring sex ratio, with 24 daughters and 16 
sons. These biases may therefore reflect either a genuinely biased transmission mechanism, or 
an ascertainment bias favouring recognition of families in which affected females 
predominate, and especially those in which affected mothers have passed the condition on to 
affected daughters. Overall, there is no significant bias in the proportion of transmissions to 
sons vs daughters (P>0.2, Chi-squared with continuity correction). 
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DISCUSSION 
 
Transmission characteristics and segregation ratios – Previous reports have differed as to 
whether the sex ratio is equal amongst MD patients. Some reports have concluded an equal 
ratio for sporadic Ménière’s disease 34, while others report a modest female preponderance 33. 
The senior author’s earlier series of Familial MD however, reported a preponderance of 
affected females, 70, compared with 49 affected males 29. Examination of the pedigrees in this 
current updated larger series now suggests only a very weak female predominance. However, 
when the patients with partial syndromes were included in the sex ratio analysis, the female 
predominance becomes much stronger. Why more females appear to have partial syndromes 
remains unclear. 
 
Mode of inheritance  
 
Martini 21 reported two families suggesting autosomal dominant inheritance.  The first 
consisted of three affected individuals, a mother and two daughters all with an early age of 
onset.  The second covered three generations of affected males and showed apparent 
anticipation, though this was not mentioned in the paper. Birgerson et al. 36 provided eleven 
pedigrees.  They concluded that eight of the families were compatible with either autosomal 
or an X-linked dominant inheritance and that three could be recessive.  In one family an 
affected mother and daughter both had a structural abnormality of chromosome 7 in some of 
their cells.  This paper is concerned also with autoimmune disease.  No age of onset data are 
provided. In 1992 a Brazilian report by Oliveira and Braga 37 suggested autosomal dominant 
inheritance based on one family: the affected father had two of eight children with MD and 
when widowed his second family of six produced one with MD. Though not commented 
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upon, this family shows possible anticipation. 
 
From Essen in Germany, Arweiler et al 38 describe five families with apparent autosomal 
dominant inheritance. Anticipation is recorded, especially in their four-generation family E, 
the age of onset in the generation F1 being of the order of 50 years, falling to 20 years in F4. 
A Canadian publication, reported in 1992 by Fung et al 39, involved six affected across two 
families, both families showing autosomal dominant inheritance and anticipation. In 2002 a 
research letter by Lynch and Cameron 40 described eight families with autosomal dominant 
MD, six showing definite anticipation on which they comment.  One family involved siblings 
only and the eighth included an unspecified youngster. The recent Finnish paper 8 suggests 
autosomal dominant as the most likely mode in most of the reported families. 
 
These studies seem to converge on autosomal dominant as the most likely mode of 
inheritance over a wide range of sources. Apparent age-of-onset anticipation is widely 
prevalent. There have been several kinds of objection raised to the possibility of genetic 
anticipation. The primary objection is that apparent anticipation is due to ascertainment bias – 
for every pair characterised by late onset in the parental generation and early onset in the 
offspring generation, there should be a corresponding pair with early onset parent and late 
onset offspring. The latter are argued to be less often ascertained because the offspring have 
not yet got their disease and/or the parents have died or been less fertile because of their 
severe disease. The ascertainment scheme employed in the collection of this family series was 
susceptible to the former bias, but there is no evidence that MD patients die early or have 
significantly reduced fertility, ruling out one potential source of bias. The best that can be said 
is that the jury is still out and that rigorous analyses of a larger series with correction for all 
known forms of ascertainment bias are required before the question can be settled. 
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In conclusion, Ménière’s Disease is usually sporadic but in about 5% there is a positive 
family association. Between 1992 and 2005, sixty-one families with possible Familial Disease 
were identified in the UK. Full pedigrees were checked and after stringent reassessment of 
these families based on AAO-HNS CHE 1995 diagnostic criteria 15 families were excluded.  
The remaining Forty-six families with Familial Ménière’s Disease represent a unique series 
and have been studied further.  120 individuals from within these families have suffered 
classical Ménière’s Disease.  Autosomal dominant inheritance with reduced penetrance 
(approximately 60 %) was the most likely mode of inheritance overall. Apparent genetic 
anticipation may be observed, but as a caution, this may also be a result of ascertainment bias 
given the collection strategy. There is perhaps a mild female predominance for Familial 
Ménière’s disease in the series, and a strong tendency for females to be diagnosed with partial 
Ménière’s syndromes. There was also a slight tendency for cases to result from maternal 
transmission within the families in this set and for affected offspring to be of the same sex as 
their affected parent. All of these observations may also be influenced by the recruitment 
strategy, which may have resulted in an ascertainment bias towards families with more female 
cases. The family pedigrees are presented and a website has been set up to allow professionals 
to view the families in greater detail. Genetic mapping studies have been carried out and will 
be reported elsewhere. 
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LEGENDS TO FIGURES 
 
 
Legend for Figure 1 
 
 
Comparison in Age of Onset of Sporadic Ménière’s Disease vs Familial Ménière’s Disease. 
(In bilateral cases the age of onset refers to the first affected ear. Sporadic MD n = 406, 
Familial MD n = 116). 
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Legend for Figure 2 
 
The graph shows age of onset (AOO) in parent-child pairs amongst the families reported here. 
One pair has been selected per family. Where more than one possible pair was present, the 
most conservative (smallest difference in AOO between the generations) was usually chosen. 
Where the most conservative pair included the proband, the alternative pair was chosen 
instead. This helps control for proband selection bias. Two series are plotted, those where the 
proband was in the parental generation (proband parent) and those where the proband was in 
the offspring generation (proband child). The diagonal line indicates equity of AOO between 
generations. 
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Legend to Figure 3 
Familial Ménière’s Disease Pedigrees of 19 families 
 
Key to figure 3 
= Unaffected Female 
= Affected Female 
= Unaffected Male 
= Affected Male 
= Partial Syndrome (possible or probable MD) 
= Proband 
Horizontal line above individual = has been personally examined for diagnosis or exclusion 
of diagnosis by authors 
 ‘BPPV’ = benign paroxysmal positional vertigo in probable and possible MD cases and in 
unaffected relatives 
‘nn  yrs’ = age of individual in 2003 or age at death 
‘Onset nn yrs’ = age of affected individual at first clear symptom of MD 
 
 
? 
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Legend to Table 1 
Transmission patterns by gender in the 46 families 
 
 
 
Table 1 
 
 
 
 
Transmitting parent 
 
Mother Father Total 
Sex of offspring     
Daughter 41 11 52 
Son 15 24 39 
Total 56 35 91 
 
 
Legend to Table 2 
Diagnostic schema and severity scale 
Table 2 
 
Diagnostic 
Status 
AAO-HNS CHE criteria AAO Severity scale Morrison Severity Scale 
Definite Vertigo – ≥2 attacks >20mins 
Hearing Loss – 25dB on affected 
side 
Tinnitus – Present 
or 
Aural Fullness - Present 
Stage 1 - ≤25dB 
Stage 2 - 26-40dB 
Stage 3 – 41-70dB 
Stage 4 - >70dB 
 
Functional Scale – 0-6 for 
degree of vertigo-related 
incapacitation 
Class 1 (Mild) – ≤35dB 
Class 2 (Moderate) – 35-50dB 
Class 3 (Severe) - >50dB to sub-total; 
bilateral; drop attacks; patients with 
AOO incapacity scale scores of 4-6 
Probable Vertigo – ≥1 attack 
Hearing Loss – Present and 
measured on ≥1 occasion 
Tinnitus – Present 
or 
Aural Fullness - Present 
  
Possible Vertigo – present (Ménière type, 
but without Hearing Loss) 
or 
Hearing Loss – Present, fixed or 
fluctuant, with disequilibrium but 
no definite episodes 
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SUMMARY 
 
• Ménière’s disease (MD) is not uncommon, with an incidence in Caucasians of about 
one in 2000.  It is of midlife onset, peaking in the fifth decade.  
• It is known that cases are usually sporadic, but in a small proportion other family 
members are affected.   
• We report here the clinical and genetic characteristics of the largest comprehensive set 
of familial MD cases yet identified, all from the U.K. Over 12 years, 61 families with 
multiple members suffering vestibular symptoms were identified. Of these 46 families 
had more then one member with true MD and these families contain 120 MD patients, 
who have been comprehensively studied. 
 
• Familial cases of Ménière’s Disease in the UK make up about 5% of the MD 
population. 
• Autosomal dominant inheritance with reduced penetrance was the most likely mode of 
inheritance overall. Apparent genetic anticipation is observed, but may also be a result 
of ascertainment bias given the collection strategy. There was also a slight tendency 
for cases to result from maternal transmission within the families in this set. The 
family pedigrees are presented and a website has been set up to allow professionals to 
view the family set in greater detail.  
• Genetic mapping studies from these pedigrees have been carried out and will be 
reported shortly in independent publication.  
 
 
